Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Anti-B7-1 Antibody-PE (4I630) (Synonyms: CD80 molecule)

Catalog No. TMAY-01080P Copy Product Info
🥰Excellent
Anti-B7-1 Antibody-PE (4I630) is a PE-conjugated Mouse antibody targeting B7-1. Anti-B7-1 Antibody-PE (4I630) can be used in FCM.

Anti-B7-1 Antibody-PE (4I630)

Copy Product Info
🥰Excellent
Catalog No. TMAY-01080P
Synonyms CD80 molecule

Anti-B7-1 Antibody-PE (4I630) is a PE-conjugated Mouse antibody targeting B7-1. Anti-B7-1 Antibody-PE (4I630) can be used in FCM.

Anti-B7-1 Antibody-PE
(4I630)
Pack SizePriceUSA StockGlobal StockQuantity
25 T$827-10 days7-10 days
100 T$1757-10 days7-10 days
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Anti-B7-1 Antibody-PE (4I630) is a PE-conjugated Mouse antibody targeting B7-1. Anti-B7-1 Antibody-PE (4I630) can be used in FCM.
SynonymsCD80 molecule
Ig Type
Mouse IgG1
Clone
4I630
Reactivity
Human
Specificity
Human B7-1/CD80
Verified Activity
Profile of anti-B7-1 (CD80) reactivity on Daudi cells analyzed by flow cytometry.
Application
Recommended Dose
10 μl/Test, 0.1 mg/ml
Antibody Type
Monoclonal
Host SpeciesMouse
ConstructionThis antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD80 / B7-1 (rh CD80 / B7-1; TMPY-01063; NP_005182.1; Met1-Asn242) and conjugated with PE under optimum conditions, the unreacted PE was removed.
PurificationProtein A
AppearanceLiquid
FormulationPBS solution containing 0.5% BSA and 0.03%ProClin300
Research BackgroundThe B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy
Related Conjugates and Formulations
Conjucates
PE
Others Formats
Unconjugated/Biotin/FITC
Antibody Types Available
4
Antigen Details
Immunogen
Recombinant Protein: Human CD80 / B7-1 protein (TMPY-01063)
Antigen Species
Human
Biology Area
Cancer Drug Targets
Chemical Properties
Stability & Storage
Stability & StorageStore at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight.
TransportShipping with blue ice.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Anti-B7-1 Antibody-PE (4I630) | purchase Anti-B7-1 Antibody-PE (4I630) | Anti-B7-1 Antibody-PE (4I630) cost | order Anti-B7-1 Antibody-PE (4I630)